Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that a new and unique neuroscience research collaboration has been established to focus on novel therapeutic approaches to managing some of the most challenging diseases that society faces today.
Population growth and increased longevity are combining in a way that has seen the prevalence of brain diseases grow significantly and the burden on society has dramatically increased. Israel is a world leader in neuroscience research, ranked 5th globally in Neuroscience publications per capita. This initiative, the National Network of Excellence in Neuroscience (NNE), seeks to harness that expertise in a community drawn from 10 of the leading universities and teaching hospitals in Israel.
Working as an open-network, the NNE is directed towards the discovery and development of new treatments and approaches to counter the devastating effects of neurological, neurodegenerative and psychiatric illness. It brings the researchers together and provides a working interface with industry, where experts in drug development from Teva will interact with academic researchers in order to increase the potential to translate basic science into therapeutic options.
Research projects supported by the NNE are already providing some important clues towards progress in key treatment modalities. Some of these projects have already identified approaches to treatment which may modify the course and progression of diseases.
In Alzheimer's disease, where loss of memory and learning ability lead to most devastating effects, approaches to enhance memory are being explored. Additionally, Multiple Sclerosis and Huntington disease are two areas where new approaches that aim to stop or reverse the progression of the disease are being investigated.
"I want to beat Multiple Sclerosis and send my patients back to their lives," said Professor Anat Achiron, Director of the Multiple Sclerosis Center at Sheba Medical Center. "The NNE initiative has enabled us to progress with a new compound, which already shows promising early results towards potentially having a new treatment modality in Multiple Sclerosis, which may one day even mean we can close our wonderful MS treatment center."